Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yu Ping Chang

Showing results (221-230 of 224) with videos related to

Pageof 23
Sort By:
You have reached the last page of results.This site can display upto 224 results.
BMC Cancer|November 9, 2016
Impact of clinical parameters and systemic inflammatory status on epidermal growth factor receptor-mutant non-small cell lung cancer patients readministration with epidermal growth factor receptor tyrosine kinase inhibitorsYu-Mu Chen, Chien-Hao Lai, Kun-Ming Rau, et al.
Lung Cancer (Amsterdam, Netherlands)|July 10, 2016
Advanced non-Small cell lung cancer patients at the extremes of age in the era of epidermal growth factor receptor tyrosine kinase inhibitorsYu-Mu Chen, Chien-Hao Lai, Kun-Ming Rau, et al.
Gut|January 20, 2026
Steatosis grade and cardiometabolic burden as determinants of hepatocellular carcinoma risk after hepatitis C cure in patients with metabolic dysfunction-associated steatotic liver diseaseYu-Ping Chang, Yun-Chu Chen, Pin-Nan Cheng, et al.
Plos One|December 9, 2016
A Survival Scoring System for Non-Small Cell Lung Cancer Patients with De Novo Bone MetastasesYu-Mu Chen, Ying-Tang Fang, Chien-Hao Lai, et al.
Pageof 23

Showing results (221-230 of 224) with videos related to

Sort By:
Pageof 23
You have reached the last page of results.This site can display upto 224 results.
BMC Cancer|November 9, 2016
Impact of clinical parameters and systemic inflammatory status on epidermal growth factor receptor-mutant non-small cell lung cancer patients readministration with epidermal growth factor receptor tyrosine kinase inhibitorsYu-Mu Chen, Chien-Hao Lai, Kun-Ming Rau, et al.
Lung Cancer (Amsterdam, Netherlands)|July 10, 2016
Advanced non-Small cell lung cancer patients at the extremes of age in the era of epidermal growth factor receptor tyrosine kinase inhibitorsYu-Mu Chen, Chien-Hao Lai, Kun-Ming Rau, et al.
Gut|January 20, 2026
Steatosis grade and cardiometabolic burden as determinants of hepatocellular carcinoma risk after hepatitis C cure in patients with metabolic dysfunction-associated steatotic liver diseaseYu-Ping Chang, Yun-Chu Chen, Pin-Nan Cheng, et al.
Plos One|December 9, 2016
A Survival Scoring System for Non-Small Cell Lung Cancer Patients with De Novo Bone MetastasesYu-Mu Chen, Ying-Tang Fang, Chien-Hao Lai, et al.
Pageof 23